Intrinsic value of Genesis Healthcare - GEN

Previous Close

$1.43

  Intrinsic Value

$0.00

stock screener

  Rating & Target

str. sell

-100%

Previous close

$1.43

 
Intrinsic value

$0.00

 
Up/down potential

-100%

 
Rating

str. sell

We calculate the intrinsic value of GEN stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Shares outstanding, mln

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  2.01
  2.00
  2.30
  2.57
  2.81
  3.03
  3.23
  3.41
  3.57
  3.71
  3.84
  3.95
  4.06
  4.15
  4.24
  4.31
  4.38
  4.44
  4.50
  4.55
  4.59
  4.64
  4.67
  4.70
  4.73
  4.76
  4.78
  4.81
  4.83
  4.84
  4.86
Revenue, $m
  5,732
  5,481
  5,608
  5,752
  5,913
  6,093
  6,289
  6,504
  6,736
  6,985
  7,253
  7,540
  7,846
  8,172
  8,518
  8,886
  9,275
  9,687
  10,123
  10,584
  11,070
  11,583
  12,124
  12,695
  13,296
  13,929
  14,595
  15,297
  16,035
  16,811
  17,628
Variable operating expenses, $m
 
  5,295
  5,416
  5,555
  5,710
  5,883
  6,072
  6,278
  6,501
  6,741
  6,999
  7,252
  7,546
  7,859
  8,192
  8,546
  8,920
  9,317
  9,736
  10,179
  10,647
  11,140
  11,661
  12,209
  12,787
  13,396
  14,037
  14,711
  15,421
  16,168
  16,954
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  5,346
  5,295
  5,416
  5,555
  5,710
  5,883
  6,072
  6,278
  6,501
  6,741
  6,999
  7,252
  7,546
  7,859
  8,192
  8,546
  8,920
  9,317
  9,736
  10,179
  10,647
  11,140
  11,661
  12,209
  12,787
  13,396
  14,037
  14,711
  15,421
  16,168
  16,954
Operating income, $m
  387
  187
  192
  197
  203
  210
  218
  226
  235
  244
  255
  288
  300
  313
  326
  340
  355
  371
  387
  405
  424
  443
  464
  486
  509
  533
  558
  585
  614
  643
  674
EBITDA, $m
  641
  619
  633
  650
  668
  688
  710
  735
  761
  789
  819
  852
  886
  923
  962
  1,004
  1,048
  1,094
  1,144
  1,196
  1,250
  1,308
  1,370
  1,434
  1,502
  1,573
  1,649
  1,728
  1,811
  1,899
  1,991
Interest expense (income), $m
  446
  499
  353
  363
  374
  387
  401
  417
  434
  452
  472
  493
  516
  540
  566
  594
  623
  654
  687
  721
  758
  796
  837
  880
  925
  973
  1,023
  1,076
  1,132
  1,191
  1,252
Earnings before tax, $m
  -136
  -312
  -161
  -165
  -171
  -177
  -183
  -191
  -199
  -208
  -217
  -205
  -216
  -228
  -240
  -254
  -268
  -283
  -299
  -316
  -334
  -353
  -373
  -394
  -417
  -440
  -465
  -491
  -519
  -547
  -578
Tax expense, $m
  -18
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -64
  -312
  -161
  -165
  -171
  -177
  -183
  -191
  -199
  -208
  -217
  -205
  -216
  -228
  -240
  -254
  -268
  -283
  -299
  -316
  -334
  -353
  -373
  -394
  -417
  -440
  -465
  -491
  -519
  -547
  -578

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  51
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  5,779
  4,885
  4,998
  5,126
  5,270
  5,430
  5,606
  5,796
  6,003
  6,226
  6,465
  6,720
  6,993
  7,283
  7,592
  7,920
  8,267
  8,634
  9,023
  9,433
  9,866
  10,324
  10,806
  11,314
  11,850
  12,414
  13,008
  13,633
  14,291
  14,983
  15,711
Adjusted assets (=assets-cash), $m
  5,728
  4,885
  4,998
  5,126
  5,270
  5,430
  5,606
  5,796
  6,003
  6,226
  6,465
  6,720
  6,993
  7,283
  7,592
  7,920
  8,267
  8,634
  9,023
  9,433
  9,866
  10,324
  10,806
  11,314
  11,850
  12,414
  13,008
  13,633
  14,291
  14,983
  15,711
Revenue / Adjusted assets
  1.001
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
  1.122
Average production assets, $m
  4,118
  4,095
  4,189
  4,296
  4,417
  4,551
  4,698
  4,858
  5,031
  5,218
  5,418
  5,633
  5,861
  6,105
  6,363
  6,638
  6,929
  7,236
  7,562
  7,906
  8,269
  8,653
  9,057
  9,483
  9,932
  10,405
  10,903
  11,427
  11,978
  12,558
  13,168
Working capital, $m
  201
  -291
  -297
  -305
  -313
  -323
  -333
  -345
  -357
  -370
  -384
  -400
  -416
  -433
  -451
  -471
  -492
  -513
  -537
  -561
  -587
  -614
  -643
  -673
  -705
  -738
  -774
  -811
  -850
  -891
  -934
Total debt, $m
  5,040
  3,562
  3,663
  3,778
  3,908
  4,052
  4,210
  4,381
  4,567
  4,768
  4,983
  5,213
  5,458
  5,720
  5,998
  6,292
  6,605
  6,935
  7,285
  7,654
  8,044
  8,456
  8,890
  9,348
  9,830
  10,337
  10,872
  11,435
  12,027
  12,650
  13,305
Total liabilities, $m
  6,270
  4,397
  4,498
  4,614
  4,743
  4,887
  5,045
  5,217
  5,403
  5,603
  5,818
  6,048
  6,294
  6,555
  6,833
  7,128
  7,440
  7,771
  8,120
  8,490
  8,880
  9,291
  9,725
  10,183
  10,665
  11,173
  11,707
  12,270
  12,862
  13,485
  14,140
Total equity, $m
  -490
  489
  500
  513
  527
  543
  561
  580
  600
  623
  646
  672
  699
  728
  759
  792
  827
  863
  902
  943
  987
  1,032
  1,081
  1,131
  1,185
  1,241
  1,301
  1,363
  1,429
  1,498
  1,571
Total liabilities and equity, $m
  5,780
  4,886
  4,998
  5,127
  5,270
  5,430
  5,606
  5,797
  6,003
  6,226
  6,464
  6,720
  6,993
  7,283
  7,592
  7,920
  8,267
  8,634
  9,022
  9,433
  9,867
  10,323
  10,806
  11,314
  11,850
  12,414
  13,008
  13,633
  14,291
  14,983
  15,711
Debt-to-equity ratio
  -10.286
  7.290
  7.330
  7.370
  7.420
  7.460
  7.510
  7.560
  7.610
  7.660
  7.710
  7.760
  7.810
  7.850
  7.900
  7.950
  7.990
  8.030
  8.070
  8.110
  8.150
  8.190
  8.230
  8.260
  8.300
  8.330
  8.360
  8.390
  8.420
  8.440
  8.470
Adjusted equity ratio
  -0.094
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -64
  -312
  -161
  -165
  -171
  -177
  -183
  -191
  -199
  -208
  -217
  -205
  -216
  -228
  -240
  -254
  -268
  -283
  -299
  -316
  -334
  -353
  -373
  -394
  -417
  -440
  -465
  -491
  -519
  -547
  -578
Depreciation, amort., depletion, $m
  254
  432
  442
  453
  465
  478
  493
  509
  526
  545
  565
  563
  586
  610
  636
  664
  693
  724
  756
  791
  827
  865
  906
  948
  993
  1,040
  1,090
  1,143
  1,198
  1,256
  1,317
Funds from operations, $m
  -57
  121
  281
  287
  294
  301
  309
  318
  327
  337
  347
  358
  370
  383
  396
  410
  425
  440
  457
  474
  493
  512
  532
  554
  576
  600
  625
  652
  679
  708
  739
Change in working capital, $m
  -125
  -6
  -7
  -8
  -9
  -10
  -10
  -11
  -12
  -13
  -14
  -15
  -16
  -17
  -18
  -19
  -21
  -22
  -23
  -24
  -26
  -27
  -29
  -30
  -32
  -34
  -35
  -37
  -39
  -41
  -43
Cash from operations, $m
  68
  126
  288
  295
  303
  311
  320
  329
  339
  350
  362
  374
  386
  400
  414
  429
  445
  462
  480
  499
  518
  539
  561
  584
  608
  634
  661
  689
  718
  750
  782
Maintenance CAPEX, $m
  0
  -401
  -409
  -419
  -430
  -442
  -455
  -470
  -486
  -503
  -522
  -542
  -563
  -586
  -610
  -636
  -664
  -693
  -724
  -756
  -791
  -827
  -865
  -906
  -948
  -993
  -1,040
  -1,090
  -1,143
  -1,198
  -1,256
New CAPEX, $m
  -201
  -83
  -94
  -108
  -121
  -134
  -147
  -160
  -173
  -187
  -200
  -214
  -229
  -243
  -259
  -274
  -291
  -308
  -326
  -344
  -363
  -383
  -404
  -426
  -449
  -473
  -498
  -524
  -551
  -580
  -610
Cash from investing activities, $m
  -13
  -484
  -503
  -527
  -551
  -576
  -602
  -630
  -659
  -690
  -722
  -756
  -792
  -829
  -869
  -910
  -955
  -1,001
  -1,050
  -1,100
  -1,154
  -1,210
  -1,269
  -1,332
  -1,397
  -1,466
  -1,538
  -1,614
  -1,694
  -1,778
  -1,866
Free cash flow, $m
  55
  -358
  -216
  -232
  -248
  -265
  -282
  -301
  -320
  -340
  -361
  -382
  -405
  -429
  -455
  -481
  -509
  -538
  -569
  -601
  -635
  -671
  -708
  -748
  -789
  -832
  -878
  -925
  -976
  -1,028
  -1,084
Issuance/(repayment) of debt, $m
  -54
  -1,475
  101
  116
  130
  144
  158
  172
  186
  200
  215
  230
  245
  261
  278
  295
  312
  331
  350
  369
  390
  412
  434
  458
  482
  508
  535
  563
  592
  623
  655
Issuance/(repurchase) of shares, $m
  0
  1,884
  172
  178
  185
  193
  201
  210
  220
  230
  241
  230
  243
  257
  271
  287
  303
  320
  338
  357
  378
  399
  421
  445
  470
  497
  524
  554
  584
  617
  651
Cash from financing (excl. dividends), $m  
  -66
  409
  273
  294
  315
  337
  359
  382
  406
  430
  456
  460
  488
  518
  549
  582
  615
  651
  688
  726
  768
  811
  855
  903
  952
  1,005
  1,059
  1,117
  1,176
  1,240
  1,306
Total cash flow (excl. dividends), $m
  -10
  52
  57
  62
  67
  72
  76
  81
  86
  91
  96
  78
  83
  89
  94
  100
  106
  112
  119
  125
  132
  140
  147
  155
  163
  172
  181
  191
  201
  211
  222
Retained Cash Flow (-), $m
  54
  -1,884
  -172
  -178
  -185
  -193
  -201
  -210
  -220
  -230
  -241
  -230
  -243
  -257
  -271
  -287
  -303
  -320
  -338
  -357
  -378
  -399
  -421
  -445
  -470
  -497
  -524
  -554
  -584
  -617
  -651
Prev. year cash balance distribution, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  11
  11
  11
  12
  12
  12
  13
  13
  13
  14
  15
  15
  16
  16
  17
  18
  19
  19
  20
  21
  22
  23
  24
  25
  27
  28
  29
  31
  32
  34
Cash available for distribution, $m
 
  -1,833
  -115
  -116
  -118
  -121
  -125
  -129
  -134
  -139
  -145
  -152
  -160
  -168
  -177
  -187
  -197
  -208
  -220
  -232
  -245
  -259
  -274
  -290
  -307
  -324
  -343
  -363
  -384
  -405
  -429
Discount rate, %
 
  15.40
  16.17
  16.98
  17.83
  18.72
  19.65
  20.64
  21.67
  22.75
  23.89
  25.08
  26.34
  27.66
  29.04
  30.49
  32.02
  33.62
  35.30
  37.06
  38.92
  40.86
  42.90
  45.05
  47.30
  49.67
  52.15
  54.76
  57.50
  60.37
  63.39
PV of cash for distribution, $m
 
  -1,588
  -85
  -73
  -61
  -51
  -42
  -35
  -28
  -22
  -17
  -13
  -10
  -7
  -5
  -3
  -2
  -2
  -1
  -1
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Current shareholders' claim on cash, %
  100
  50.0
  37.0
  27.2
  20.0
  14.7
  10.7
  7.8
  5.6
  4.1
  2.9
  2.2
  1.6
  1.2
  0.8
  0.6
  0.4
  0.3
  0.2
  0.2
  0.1
  0.1
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Genesis Healthcare, Inc. is a holding company that provides post-acute care. The Company operates through three segments: inpatient services, which includes the operation of skilled nursing facilities and assisted or senior living facilities; rehabilitation therapy services, which includes its integrated and third-party rehabilitation and respiratory therapy services, and all other services. As of December 31, 2016, the Company offered inpatient services through its network of 499 skilled nursing and assisted/senior living facilities across 34 states, consisting of 473 skilled nursing facilities and 26 stand-alone assisted/senior living facilities. Its services focus primarily on the medical and physical issues facing elderly patients and are provided by its skilled nursing companies, assisted or senior living communities, integrated and third-party rehabilitation therapy business, and other ancillary services.

FINANCIAL RATIOS  of  Genesis Healthcare (GEN)

Valuation Ratios
P/E Ratio -3.5
Price to Sales 0
Price to Book -0.5
Price to Tangible Book
Price to Cash Flow 3.2
Price to Free Cash Flow -1.7
Growth Rates
Sales Growth Rate 2%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate -20.6%
Cap. Spend. - 3 Yr. Gr. Rate 17.4%
Financial Strength
Quick Ratio 2
Current Ratio 0.1
LT Debt to Equity -1022.9%
Total Debt to Equity -1028.6%
Interest Coverage 1
Management Effectiveness
Return On Assets 5.5%
Ret/ On Assets - 3 Yr. Avg. 3.6%
Return On Total Capital -1.4%
Ret/ On T. Cap. - 3 Yr. Avg. -7.4%
Return On Equity 13.8%
Return On Equity - 3 Yr. Avg. 82.5%
Asset Turnover 1
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin 9.8%
EBITDA Margin - 3 Yr. Avg. 7%
Operating Margin 6.7%
Oper. Margin - 3 Yr. Avg. 4.2%
Pre-Tax Margin -2.4%
Pre-Tax Margin - 3 Yr. Avg. -4.9%
Net Profit Margin -1.1%
Net Profit Margin - 3 Yr. Avg. -4.7%
Effective Tax Rate 13.2%
Eff/ Tax Rate - 3 Yr. Avg. -6.6%
Payout Ratio 0%

GEN stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the GEN stock intrinsic value calculation we used $5374 million for the last fiscal year's total revenue generated by Genesis Healthcare. The default revenue input number comes from 2016 income statement of Genesis Healthcare. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our GEN stock valuation model: a) initial revenue growth rate of 2% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 15.4%, whose default value for GEN is calculated based on our internal credit rating of Genesis Healthcare, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Genesis Healthcare.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of GEN stock the variable cost ratio is equal to 96.6%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for GEN stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 9.9% for Genesis Healthcare.

Corporate tax rate of 27% is the nominal tax rate for Genesis Healthcare. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the GEN stock is equal to 0.2%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for GEN are equal to 74.7%.

Life of production assets of 10 years is the average useful life of capital assets used in Genesis Healthcare operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for GEN is equal to -5.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $-1084 million for Genesis Healthcare - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 94 million for Genesis Healthcare is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Genesis Healthcare at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
ENSG Ensign Group 37.92 13.43  sell
NHC National Healt 70.30 15.32  str.sell
DVCR Diversicare He 6.95 70.33  str.buy
ACHC Acadia Healthc 42.25 33.06  hold
FVE Five Star Seni 1.38 0.74  sell
CSU Capital Senior 9.98 0.69  str.sell

COMPANY NEWS

▶ Home DNA Testing Gains Popularity in Aging Japan   [Jul-17-18 05:00PM  Bloomberg]
▶ The 5 Best Healthcare Stocks of 2018 (So Far)   [Jul-09-18 09:06AM  Motley Fool]
▶ Genesis Healthcare: 1Q Earnings Snapshot   [May-10-18 06:13AM  Associated Press]
▶ Interim Report First Quarter 2018   [May-08-18 11:04AM  GlobeNewswire]
▶ $30M deal: Genesis to sell 51% stake in China subsidiary   [Apr-24-18 08:25AM  American City Business Journals]
▶ Genesis selling off 2 dozen skilled nursing facilities in Texas   [Apr-12-18 10:38AM  American City Business Journals]
▶ Passing of Genmab A/S Annual General Meeting   [09:43AM  GlobeNewswire]
▶ Genesis Healthcare reports 4Q loss   [06:27AM  Associated Press]
▶ At $1.17, Is Genesis Healthcare Inc (NYSE:GEN) A Buy?   [Mar-02-18 05:31PM  Simply Wall St.]
▶ [$$] Genesis Healthcare Refinances Debt Load Amid Restructuring   [Feb-23-18 05:06PM  The Wall Street Journal]
▶ Genesis Healthcare gets some debt relief   [12:45PM  American City Business Journals]
▶ Nursing home giant Genesis eyes approval for $26M Dracut facility   [Feb-08-18 04:45PM  American City Business Journals]
▶ Genesis Healthcare reports 3Q loss   [05:01AM  Associated Press]
▶ Companies Paying Americans the Least   [Oct-27-17 04:22PM  24/7 Wall St.]
▶ Genesis Healthcare reports 2Q loss   [Aug-08-17 11:59PM  Associated Press]
▶ LD Micro Index Reconstitution as of August 1, 2017   [Aug-01-17 09:40AM  ACCESSWIRE]
Financial statements of GEN
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.